Significantly, Eg5 and RNF20/40 were concurrently upregulated in breast carcinomas, and higher Eg5 protein expression was correlated with poorer survival of breast cancer patients with luminal A or B type, implicating these proteins as potential targets for cancer treatment and prevention. This evidence concerns the gene RNF20 and breast cancer.